Holen Sie sich die Stockscreener-App
0.74
14.05%
-0.121
Handel nachbörslich:
.72
-0.02
-2.70%
Schlusskurs vom Vortag:
$0.861
Offen:
$0.8218
24-Stunden-Volumen:
10.58M
Relative Volume:
5.31
Marktkapitalisierung:
$29.23M
Einnahmen:
$875.70K
Nettoeinkommen (Verlust:
$-39.57M
KGV:
-0.5513
EPS:
-1.3423
Netto-Cashflow:
$-33.65M
1W Leistung:
-81.27%
1M Leistung:
-84.02%
6M Leistung:
-64.08%
1J Leistung:
-68.10%
1-Tages-Spanne:
$0.7301
$0.8423
1-Wochen-Bereich:
$0.7301
$4.50
52-Wochen-Spanne:
$0.7301
$5.14
Vistagen Therapeutics Inc Stock (VTGN) Company Profile
Firmenname
Vistagen Therapeutics Inc
Sektor
Branche
Telefon
650-577-3600
Adresse
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Vergleichen Sie VTGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VTGN
Vistagen Therapeutics Inc
|
0.74 | 34.01M | 875.70K | -39.57M | -33.65M | -1.3423 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.38 | 114.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
748.71 | 78.80B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
396.04 | 51.80B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
847.05 | 53.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
166.55 | 42.33B | 447.02M | -1.18B | -906.14M | -6.1812 |
Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-12-07 | Hochstufung | Jefferies | Hold → Buy |
| 2023-08-07 | Hochstufung | Maxim Group | Hold → Buy |
| 2022-07-22 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-22 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-07-22 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-05-20 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-02-18 | Eingeleitet | Jefferies | Buy |
| 2021-01-04 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2018-06-27 | Eingeleitet | Maxim Group | Buy |
| 2018-02-08 | Bestätigt | Chardan Capital Markets | Buy |
| 2017-03-28 | Eingeleitet | Maxim Group | Buy |
Alle ansehen
Vistagen Therapeutics Inc Aktie (VTGN) Neueste Nachrichten
Vistagen tanks after fasedienol Phase III miss - The Pharma Letter
Jefferies Downgrades Vistagen Therapeutics to Hold From Buy, Adjusts Price Target to $0.90 From $15 - marketscreener.com
Vistagen appoints Nick Tressler as CFO - MSN
Downgrade Alert: Vistagen Therapeutics (VTGN) Target Price Slashed | VTGN Stock News - GuruFocus
Vistagen stock craters after social anxiety study comes up empty - FirstWord Pharma
Vistagen Therapeutics (VTGN) Downgraded by Maxim Group | VTGN St - GuruFocus
Vistagen Therapeutics (VTGN) Receives Downgrade from William Bla - GuruFocus
Jefferies downgrades VistaGen stock rating to Hold on failed Phase III trial - Investing.com
VistaGen stock rating downgraded by William Blair after trial miss - Investing.com Canada
Vistagen phase 3 study sees placebo surprise, putting future of social anxiety asset into question: analyst - Fierce Biotech
Vistagen’s anxiety treatment fails to meet primary endpoint in trial By Investing.com - Investing.com Nigeria
Fasedienol for Social Anxiety Disorder Does Not Demonstrate Significant Improvement in Phase 3 Study - Psychiatric Times
Maxim Downgrades Vistagen Therapeutics to Hold From Buy - marketscreener.com
William Blair Downgrades VistaGen Therapeutics(VTGN.US) to Hold Rating - 富途牛牛
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Stifel downgrades VistaGen stock to Hold as anxiety drug fails in trial - Investing.com Canada
Vistagen downgraded to Hold at Stifel after PALISADE-3 study disappoints - TipRanks
Why Did Vistagen Stock Tank 82% Today? - Stocktwits
Vistagen (VTGN) Faces Setback as Phase 3 Trial Misses Primary En - GuruFocus
Vistagen downgraded to Neutral from Buy at Lucid Capital - TipRanks
Vistagen (VTGN) Phase 3 Study Results for Social Anxiety Treatme - GuruFocus
Vistagen SAD study did not achieve primary endpoint - TipRanks
Vistagen’s anxiety treatment fails to meet primary endpoint in trial - Investing.com
Vistagen flunks late-stage trial for social anxiety drug (VTGN) - Seeking Alpha
Vistagen Announces Topline Results From Palisade-3 Phase 3 Study - TradingView — Track All Markets
Social anxiety nose-spray drug stumbles in key trial, but safety holds up - Stock Titan
Vistagen Therapeutics Earnings Notes - Trefis
Fed Meeting: Can Vistagen Therapeutics Inc stock beat analyst upgradesJuly 2025 Review & Low Drawdown Investment Strategies - moha.gov.vn
VistaGen Therapeutics (NASDAQ:VTGN) Share Price Crosses Above 50-Day Moving AverageShould You Sell? - MarketBeat
Would You Still Hold Vistagen Therapeutics Stock If It Fell 30%? - Trefis
Is Vistagen Therapeutics Inc (VTGN) positioned for future growth? - setenews.com
Can Vistagen Therapeutics Stock Recover If Markets Fall? - Trefis
Is Vistagen Therapeutics Stock Built to Withstand More Downside? - Trefis
Why Vistagen Therapeutics Inc. stock is trending among retail tradersJuly 2025 Final Week & Free Community Consensus Stock Picks - Newser
Will Vistagen Therapeutics Inc. stock pay special dividends2025 Year in Review & Reliable Entry Point Trade Alerts - Newser
VistaGen Therapeutics (NASDAQ:VTGN) Stock Price Passes Below 50 Day Moving AverageHere's Why - MarketBeat
Vistagen Therapeutics, Inc. Announces Executive Changes - marketscreener.com
Vistagen Appoints Nick Tressler as Chief Financial Officer - BioSpace
VistaGen appoints Nick Tressler as CFO - MSN
The time has not yet come to remove your chips from the table: Vistagen Therapeutics Inc (VTGN) - Setenews
Vistagen Therapeutics Appoints Nick Tressler as CFO - marketscreener.com
Vistagen (VTGN) Appoints New CFO, Nick Tressler - GuruFocus
Vistagen (VTGN) Names Nick Tressler as New CFO - GuruFocus
Vistagen Names Nick Tressler as Chief Financial Officer - Contract Pharma
Vistagen appoints Nick Tressler as chief financial officer - marketscreener.com
Vistagen (Nasdaq: VTGN) appoints CFO Nick Tressler, grants 150,000-share option - Stock Titan
Why retail investors pile into Vistagen Therapeutics Inc. stock2025 Sector Review & Technical Pattern Based Signals - BỘ NỘI VỤ
Vistagen Therapeutics Inc. (VTGN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Vistagen (VTGN) Presents Promising Data on PH80 for Menopause Sy - GuruFocus
Vistagen presents data on PH80 for menopausal hot flashes treatment By Investing.com - Investing.com Canada
Vistagen Reports Findings on PH80’s Brain and Autonomic Effects in Women with Menopausal Hot Flashes at The Menopause Society 2025 Annual Meeting - Yahoo Finance
Finanzdaten der Vistagen Therapeutics Inc-Aktie (VTGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.31%
0.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):